Varas-Lorenzo C, Castellsaque J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25.
Wolowacz S, Samuel M, Brennan VK, Jasso-Mosqueda J, van Gelder I. The cost of illness of atrial fibrillation: a systematic review. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A325.
Mauskopf J, Graham JB, Bae J, Gaich C. Impact of including prasugrel on the formulary for patients who undergo percutaneous coronary intervention for acute coronary syndrome. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A322.
Riera-Guardia N, Hirst C, Castellsague J, Varas-Lorenzo C, Pariente A, Sturkenboom MCJM, Perez-Gutthann S. The SOS project: cardiovascular and gastrointestinal safety of NSAIDS. Preliminary results of a systematic review of epidemiological studies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S207.
Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.
Loughlin J, Quinn S, Rivero E, Norman H, Earnes DL, Wong J, Seeger JD. No evidence for association of tegaserod with adverse cardiovascular ischemic events. Presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(Suppl 1):S17.
Varas-Lorenzo C, Johannes C, McQuay L, Midkiff K, Stang MR, Fife D. Validation of serious ventricular arrhythmias in an administrative database. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(S1-273):S222.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall-Vila M, Williams LK. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.
Mauskopf J, Schmitt C, Boye KS, McCollam PL, Juniper MD, Birt JA. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(2):A148.
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Chen L, Candrilli SD. Age-segmented rates of treatment, goal attainment, comorbidities and lifestyle risks among men diagnosed with hypertension and dyslipidemia in the United States. Poster presented at the 2009 Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference; April 2009.
Mauskopf JA, Boye KS, Schmitt C, McCollam P, Birt J, Juniper MD, Bakhai A. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. J Med Econ. 2009 Jan 1;12(2):141-53.
Lundbye-Christensen S, Dethlefsen C, Gorst-Rasmussen A, Fischer T, Schønheyder HC, Rothman KJ, Sørensen HT. Examining secular trends and seasonality in count data using dynamic generalized linear modeling: a new methodological approach illustrated with hospital discharge data on myocardial infarction. Eur J Epidemiol. 2009;24(5):225-30.
Rothman KJ. Bare versus drug-eluting stents in acute myocardial infarction. N Engl J Med. 2009;360:301.
Sanders J, Hawe E, Brull DJ, Hubbart C, Lowe GD, Rumley A, Humphries SE, Montgomery HE. Higher IL-6 levels but not IL6 -174G>C or -572G>C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis. 2009;204(1):196-201.
Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cycoxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016-25.